Allogene Therapeutics (ALLO) Change in Account Payables (2018 - 2026)

Allogene Therapeutics has disclosed Change in Account Payables across 9 years of filings, most recently posting $663000.0 for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $663000.0, up 297.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$232000.0 (up 67.82% YoY), and the FY2025 annual result was -$1.2 million, down 144.73% from the prior year.
• Change in Account Payables came in at $663000.0 for Q1 2026 at Allogene Therapeutics, up from $599000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.8 million in Q2 2024 to a low of -$7.2 million in Q3 2024.
• The 5-year median for Change in Account Payables is -$118000.0 (2024), against an average of -$217941.2.
• Across the five-year window, Change in Account Payables plunged 491.61% in 2023 and soared 1661.76% in 2025, its largest moves.
• Allogene Therapeutics' Change in Account Payables stood at $2.9 million in 2022, then slumped by 110.28% to -$302000.0 in 2023, then soared by 111.26% to $34000.0 in 2024, then jumped by 1661.76% to $599000.0 in 2025, then rose by 10.68% to $663000.0 in 2026.
• The last three Change in Account Payables figures came in at $663000.0 (Q1 2026), $599000.0 (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.